Literature DB >> 7507016

Soluble intercellular adhesion molecule-1 (sICAM-1) as a marker of disease relapse in idiopathic uveoretinitis.

A G Zaman1, C Edelsten, M R Stanford, E M Graham, B A Ellis, H Direskeneli, D P D'Cruz, G R Hughes, D C Dumonde, G R Wallace.   

Abstract

This study reports the results of a point prevalence study of markers of endothelial dysfunction in the serum of patients with idiopathic uveoretinitis. sICAM-1, soluble endothelial leucocyte adhesion molecule (sELAM), anti-endothelial cell antibodies (AECA) and von Willebrand factor (vWF) levels were measured in 32 patients with isolated idiopathic uveoretinitis and seven with uveitis in association with systemic disease, using commercial and in-house ELISAs. Raised levels of AECA were found in 31% of patients with isolated uveitis, vWF in 28%, sELAM in 15.6% and sICAM-1 in 31%. Further analysis revealed that raised sICAM-1 levels were closely associated with recent relapse of disease (P = 0.00003). Patients with accompanying systemic disease were found to have a similar prevalence of these serum abnormalities to those with isolated ocular disease. In conclusion, vascular endothelial dysfunction may contribute to pathogenesis in uveoretinitis, and in particular sICAM-1 may prove a marker of disease relapse in this condition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507016      PMCID: PMC1534625          DOI: 10.1111/j.1365-2249.1994.tb06015.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon.

Authors:  J S Pober; M A Gimbrone; L A Lapierre; D L Mendrick; W Fiers; R Rothlein; T A Springer
Journal:  J Immunol       Date:  1986-09-15       Impact factor: 5.422

2.  Anti-endothelial cell antibodies and circulating immune complexes in the sera of patients with multiple sclerosis.

Authors:  Y Tanaka; N Tsukada; C S Koh; N Yanagisawa
Journal:  J Neuroimmunol       Date:  1987-12       Impact factor: 3.478

3.  Activated T lymphocytes in uveitis.

Authors:  J Deschênes; D H Char; S Kaleta
Journal:  Br J Ophthalmol       Date:  1988-02       Impact factor: 4.638

4.  ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM.

Authors:  D Simmons; M W Makgoba; B Seed
Journal:  Nature       Date:  1988-02-18       Impact factor: 49.962

5.  T lymphocyte subsets in uveitis.

Authors:  R B Nussenblatt; M Salinas-Carmona; W Leake; I Scher
Journal:  Am J Ophthalmol       Date:  1983-05       Impact factor: 5.258

Review 6.  Duke-Elder lecture. Retinal arteritis, retinal vasculitis and autoimmune retinal vasculitis.

Authors:  M D Sanders
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

7.  Humoral and cellular immune responsiveness to human S-antigen in uveitis.

Authors:  G Doekes; R van der Gaag; A Rothova; Y van Kooyk; L Broersma; M J Zaal; G Dijkman; M E Fortuin; G S Baarsma; A Kijlstra
Journal:  Curr Eye Res       Date:  1987-07       Impact factor: 2.424

8.  ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells.

Authors:  M W Makgoba; M E Sanders; G E Ginther Luce; M L Dustin; T A Springer; E A Clark; P Mannoni; S Shaw
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

9.  Increased von Willebrand factor antigen in the plasma of patients with vasculitis.

Authors:  S R Nusinow; A B Federici; T S Zimmerman; J G Curd
Journal:  Arthritis Rheum       Date:  1984-12

10.  The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response.

Authors:  G J Dougherty; S Murdoch; N Hogg
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

View more
  13 in total

1.  Soluble ICAM-1 serum levels in patients with intermediate uveitis.

Authors:  A M Klok; L Luyendijk; M J Zaal; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

Review 2.  Anterior uveitis: clinical and research perspectives.

Authors:  J T Rosenbaum; T M Martin; S R Planck
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

4.  The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU).

Authors:  G R Wallace; R A Whiston; M R Stanford; G M Wells; A J Gearing; J M Clements
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 5.  Antiendothelial cell antibodies (AECA) in patients with uveoretinitis.

Authors:  C Edelsten; D P D'Cruz
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

6.  Urinary neopterin in idiopathic retinal vasculitis.

Authors:  H E Palmer; G Giovannoni; M R Stanford; G R Wallace; E M Graham
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

7.  Elevation of serum soluble intercellular adhesion molecule-1 (sICAM-1) and beta-2-microglobulin in Sjögren's syndrome.

Authors:  J Krejsek; R Slezák; O Kopecky; V Derner; C Andrys
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

8.  Vitreous levels of intercellular adhesion molecule 1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy.

Authors:  G A Limb; A H Chignell
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

Review 9.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

10.  Vitreous intercellular adhesion molecule 1 in uveitis complicated by retinal detachment.

Authors:  L Webster; R M Stanbury; A H Chignell; G A Limb
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.